Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -422.77M | -427.49M | -419.65M | -137.25M | -145.22M |
| Total Depreciation and Amortization | 1.09M | 8.55M | 8.50M | 8.84M | 16.73M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 57.05M | 44.08M | 42.82M | 42.91M | 60.43M |
| Change in Net Operating Assets | 16.94M | 12.23M | -22.53M | -327.31M | -289.93M |
| Cash from Operations | -347.69M | -362.64M | -390.86M | -412.81M | -357.99M |
| Capital Expenditure | -15.91M | -13.06M | -11.24M | -12.30M | -12.94M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -72.84M | -174.86M | -169.42M | -98.86M | 262.25M |
| Cash from Investing | -88.76M | -187.92M | -180.66M | -111.16M | 249.31M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -32.34M | -24.02M | -- | -- | -- |
| Issuance of Common Stock | 517.12M | 517.67M | 514.23M | 516.49M | 17.82M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -480.00K | -480.00K | -- | -- | -- |
| Cash from Financing | 484.30M | 493.18M | 514.23M | 516.49M | 17.82M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.85M | -57.38M | -57.29M | -7.48M | -90.86M |
